People: Genus PLC (GENS.L)

GENS.L on London Stock Exchange

1,365.00GBp
27 Feb 2015
Change (% chg)

3.00p (+0.22%)
Prev Close
1,362.00p
Open
1,376.00p
Day's High
1,376.00p
Day's Low
1,359.00p
Volume
59,749
Avg. Vol
57,933
52-wk High
1,411.27p
52-wk Low
924.50p

Search Stocks

Summary

Name Age Since Current Position

Robert Lawson

67 2010 Non-Executive Independent Chairman of the Board

Karim Bitar

47 2011 Chief Executive, Executive Director

Stephen Wilson

2013 Group Finance Director, Executive Director

Jonathan Lightner

2013 Chief R&D and Scientific Officer

Dan Hartley

2014 Group General Counsel & Company Secretary

Catherine Glickman

2012 Group Human Resources Director

Bill Christianson

2013 Chief Operating Officer - Genus PIC

Saskia Romani

2013 Acting Chief Operating Officer - Genus ABS

Jerry Thompson

2012 Chief Operating Officer, Genus Asia

Lykele Broek

2014 Non-Executive Director

Duncan Maskell

2014 Non-Executive Director

Mike Buzzacott

64 2009 Non-Executive Independent Director

Barrington Furr

70 2006 Non-Executive Independent Director

Nigel Turner

63 2008 Senior Non-Executive Independent Director

Biographies

Name Description

Robert Lawson

Mr. Robert A. Lawson serves as Non-Executive Independent Chairman of the Board of Genus PLC. Bob Lawson was appointed Chairman of the Board and the Nomination Committee in November 2010. He is Non-Executive Chairman of Barratt Developments plc and a director of The Federation of Groundwork Trusts. His career has spanned several UK and continental groups including ten years as Chief Executive of Electrocomponents plc leading its successful expansion into new international markets, and three years as Managing Director of Vitec Group plc.

Karim Bitar

Mr. Karim Bitar serves as Chief Executive, Executive Director of Genus PLC. Karim Bitar joined the Board in September 2011. He worked for over 15 years with Eli Lilly and Company and was President of Lilly Europe, Canada and Australia before joining Genus. An ex-McKinsey & Company consultant, he worked across Asia and in Europe, and also held management roles at Johnson & Johnson and the Dow Chemical Company.

Stephen Wilson

Mr. Stephen Wilson serves as Group Finance Director, Executive Director of Genus PLC. Stephen Wilson joined the Board in January 2013 and was appointed Group Finance Director on 1 March 2013. He was previously Executive Vice President and Chief Financial Officer of Misys plc, the financial services software provider that was a FTSE 250 company until its acquisition by Vista Equity Partners. Prior to Misys, Stephen was Vice President and CFO of IBM United Kingdom Limited. He is a Fellow of the Chartered Institute of Management Accountants and is a Non-Executive Director and Chairman of the Audit Committee of Xchanging plc. He holds a degree in Mathematics from the University of Cambridge.

Jonathan Lightner

Dr. Jonathan Lightner is Chief R&D and Scientific Officer of Genus PLC. Jonathan is a world renowned molecular and quantitative geneticist, whose career has encompassed R&D, regulatory and commercial activities. He joined us in October 2013 from Pioneer Hi-bred International Inc, a DuPont business, where he was Vice President of Agricultural Biotechnology, leading a global team focused on new genetic solutions to enhance agricultural productivity. He obtained his Doctorate in Plant Physiology at the Institute of Biological Chemistry at Washington State University in 1994. He also holds a Masters in Systems Engineering from Iowa State (2009) and an MBA from the University of Iowa (2009).

Dan Hartley

Mr. Dan Hartley is Group General Counsel & Company Secretary of Genus PLC. After being admitted to practice law in Australia, Dan worked initially with Allens Arthur Robinson and then Anderson Legal on biotech patent litigation and in 2000, he moved to Freshfields Bruckhaus Deringer in the UK. In 2002, he joined Shire Pharmaceuticals where he held a number of roles of increasing seniority including; General Counsel for Europe; a three year secondment to the US; and Global Counsel for Shire's biologics business, before being appointed Shire's International Counsel for all ex-US operations. He graduated in Organic Chemistry from Sydney University, before studying for a law degree from the University of Wollongong.

Catherine Glickman

Ms. Catherine Glickman has been Group Human Resources Director of Genus Plc. Catherine joined Genus in January 2012, in the newly created role of Group HR Director. For the previous 20 years, she worked for Tesco plc in a variety of positions. For the last four years she was Group HR Director, where she focused on talent development, succession and leadership development. She held HR Director roles supporting Tesco’s roll-out into Asia, Central Europe and the United States, and led HR for the UK stores during a period of major expansion. Prior to Tesco, she worked in HR for Somerfield plc and Boots plc. Catherine holds a degree in English Language and Literature from Durham University and is a member of the Institute of Personnel and Development.

Bill Christianson

Mr. Bill Christianson serves as Chief Operating Officer - Genus PIC of Genus PLC. Bill has doctorates in Veterinary Medicine and Philosophy from the University of Minnesota. He joined Genus in 1993. Before his current appointment in July 2012, he held various operational roles within Genus, including serving as General Manager of the PIC North America business in 2007 and as Chief Operating Officer of the Americas from March 2010.

Saskia Romani

Ms. Saskia Korink Romani is Acting Chief Operating Officer - Genus ABS of Genus PLC. Saskia joined Genus in January 2013 as Chief Marketing Officer. She was Acting Chief Operating Officer for Genus ABS from July 2013, before being appointed permanently in January 2014. For the previous ten years, she worked for Cargill Inc., most recently as the Vice President of Marketing for Cargill’s animal nutrition business. Saskia has worked across Europe, Latin America and North America, and brings significant business experience having been at Boston Consulting Group for seven years. She is originally a physicist and began her career in engineering and packaging design with Unilever PLC. She has an MBA from Columbia Business School.

Jerry Thompson

Mr. Jerry Thompson is Chief Operating Officer, Genus Asia of Genus PLC. Jerry graduated with a BSc Hons in Agriculture from Seale Hayne College, Devon, and has worked for PIC and subsequently Genus for over 20 years. After two years in the UK business, he moved to Eastern Europe where he has held a number of roles including Key Account Manager in Siberia, and Managing Director for PIC Romania and for the Central and Eastern European PIC business. In 2008, Jerry moved to the position of Regional Director for PIC Europe. He became Regional Director for the Russia and Asia Pacific Region, based in Shanghai in 2010, before being appointed to his current role on 1 July 2012.

Lykele Broek

Lykele van der Broek is Non-Executive Director of Genus PLC. Lykele van der Broek joined the Board in July 2014. He has a Master of Science degree from the Agricultural University in Wageningen, the Netherlands. Prior to his retirement as a member of the Executive Committee of Bayer CropScience, a division of Bayer AG, on 31 July 2014, he held various senior international roles, including Head of the Bayer CropScience BioScience division and President of the Bayer HealthCare Animal Health division.

Duncan Maskell

Professor Duncan Maskell is Non-Executive Director of Genus PLC. Duncan Maskell joined the Board in April 2014. He is Head of the School of the Biological Sciences, University of Cambridge, one of the University’s most senior positions. He has been instrumental in co-founding several biotech companies and has extensive experience of advising companies on science and innovation. In the past, he has worked on new vaccines against salmonella and bordetella at Wellcome Biotech, and on bacteria that cause childhood meningitis at the Institute of Molecular Medicine, University of Oxford. He currently heads a large research group at Cambridge, working on infectious diseases of livestock and people.

Mike Buzzacott

Mr. Mike Buzzacott serves as Non-Executive Independent Director of Genus PLC. Mike Buzzacott is a qualified accountant. He joined the Board in May 2009 and is Chairman of the Audit Committee. He spent 34 years at BP prior to his retirement in 2004, holding a number of international roles including Finance & Control Director Asia Pacific, CFO BP Nutrition and Group Vice President Petrochemicals. He is currently a Non- Executive Director of Scapa Plc. He retired as a Non-Executive Director of Croda plc in August 2011 and was formerly a Non- Executive Director of Rexam plc and Chairman of Biofuels plc.

Barrington Furr

Professor Dr. Barrington J. A. Furr, Ph.D., serves as Non-Executive Independent Director of Genus PLC. Professor Furr retired as Chief Scientist and Head of Project Evaluation for AstraZeneca plc in 2005 after 34 years of service. He is a Non-Executive Director of the Medicines and Healthcare Products Regulatory Agency and the American Pharmaceutical company GTx Inc. He was awarded an OBE in 2000 for his services to cancer drug discovery. He joined the Board in December 2006 and acts as Scientific Advisor to Genus’s Research & Development Portfolio Management Team, which replaced the Science Committee with effect from 1 July 2012. He is the author of more than 160 papers on reproductive endocrinology and antihormones.

Nigel Turner

Mr. Nigel Turner serves as Senior Non-Executive Independent Director of Genus PLC. Nigel Turner joined the Board in January 2008 and is Chairman of the Remuneration Committee. He was Chairman of Numis Securities Ltd and Deputy Chairman of Numis Corporation plc from December 2005 to November 2007. He is currently a Non- Executive Director of Croda plc. Previously he was Vice Chairman of ABN AMRO’s Wholesale and Investment Bank in which he had specific responsibility for the Global Corporate Finance and Equity businesses. He joined the Dutch bank in 2000 from Lazard, where he was a partner for 15 years and also sat on its Supervisory Board.

Basic Compensation

Search Stocks